Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06180005
Status:
RECRUITING
Last Update Posted:
2023-12-22
First Post:
2023-12-11
Brief Title:
Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano INOND
Sponsor:
Centro di Riferimento Oncologico - Aviano
Organization:
Centro di Riferimento Oncologico - Aviano
Study Overview
Official Title:
Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano INOND
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INOND
Brief Summary:
According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it In addition to that therapies guided by analysis on mutations identified in ct-DNA had a favorable impact allowing longer survival All this suggests that the presence of a therapeutically targetable oncogene oncogene addicted allows target therapy resulting in a longer life expectancy The main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with NSCLC afferent to the CRO Oncogene addiction is defined as being carriers of one of the mutations among EGFR ALK RET KRAS BRAF Her2 ROS1 MET or other mutations that become therapeutic targets under investigation
Detailed Description:
According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it In addition to that therapies guided by analysis on mutations identified in ct-DNA had a favorable impact allowing longer survival All this suggests that the presence of a therapeutically targetable oncogene oncogene addicted allows target therapy resulting in a longer life expectancy The main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with NSCLC afferent to the CRO Oncogene addiction is defined as being carriers of one of the mutations among EGFR ALK RET KRAS BRAF Her2 ROS1 MET or other mutations that become therapeutic targets under investigation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None